Uppsala, Sweden, November 3, 2020 – Oasmia Pharmaceutical’s CEO, Dr Francois Martelet will present at the Investival Showcase’s digital conference November 11-16, 2020. The presentation will be made available on demand on the Investival Showcase website and accessible to attendees registered for the event. The presentation will also be uploaded onto Oasmia’s website following the event.

For more information: 
 
Oasmia Pharmaceutical AB 
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 
E-mail: IR@oasmia.com
 
Consilium Strategic Communications 
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700 
E-mail: oasmia@consilium-comms.com

About Oasmia Pharmaceutical AB
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on the Company’s proprietary drug delivery technology platform XR-17™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar).  Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.oasmia.com